[go: up one dir, main page]

DK3474841T3 - Fremgangsmåder til behandling af ar+-brystkræft - Google Patents

Fremgangsmåder til behandling af ar+-brystkræft Download PDF

Info

Publication number
DK3474841T3
DK3474841T3 DK17816081.8T DK17816081T DK3474841T3 DK 3474841 T3 DK3474841 T3 DK 3474841T3 DK 17816081 T DK17816081 T DK 17816081T DK 3474841 T3 DK3474841 T3 DK 3474841T3
Authority
DK
Denmark
Prior art keywords
procedures
treatment
breast cancer
breast
cancer
Prior art date
Application number
DK17816081.8T
Other languages
English (en)
Inventor
Gary Hattersley
Chris Miller
Teeru Bihani
Jamal Saeh
Ziyang Yu
Original Assignee
Ellipses Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellipses Pharma Ltd filed Critical Ellipses Pharma Ltd
Application granted granted Critical
Publication of DK3474841T3 publication Critical patent/DK3474841T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK17816081.8T 2016-06-22 2017-06-20 Fremgangsmåder til behandling af ar+-brystkræft DK3474841T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662353350P 2016-06-22 2016-06-22
US201662377497P 2016-08-19 2016-08-19
US201762461546P 2017-02-21 2017-02-21
PCT/US2017/038390 WO2017223115A1 (en) 2016-06-22 2017-06-20 Ar+ breast cancer treatment methods

Publications (1)

Publication Number Publication Date
DK3474841T3 true DK3474841T3 (da) 2022-05-09

Family

ID=60675862

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17816081.8T DK3474841T3 (da) 2016-06-22 2017-06-20 Fremgangsmåder til behandling af ar+-brystkræft

Country Status (21)

Country Link
US (3) US20170368036A1 (da)
EP (2) EP4066827A1 (da)
JP (2) JP7221699B2 (da)
KR (2) KR20220035276A (da)
AU (2) AU2017281038B2 (da)
CA (1) CA3027563A1 (da)
DK (1) DK3474841T3 (da)
ES (1) ES2913470T3 (da)
HR (1) HRP20220619T1 (da)
IL (2) IL292659A (da)
LT (1) LT3474841T (da)
MX (2) MX2018015724A (da)
NZ (1) NZ749192A (da)
PL (1) PL3474841T3 (da)
PT (1) PT3474841T (da)
RS (1) RS63311B1 (da)
RU (2) RU2769527C2 (da)
SG (1) SG11201811225RA (da)
SI (1) SI3474841T1 (da)
SM (1) SMT202200199T1 (da)
WO (1) WO2017223115A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
AU2017281038B2 (en) 2016-06-22 2021-09-09 Ellipses Pharma Ltd AR+ breast cancer treatment methods
MY205589A (en) 2018-01-08 2024-10-28 G1 Therapeutics Inc G1t38 superior dosage regimes
US20190240198A1 (en) * 2018-02-05 2019-08-08 Dean G. Tang Formulations and methods for the treatment of cancers
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020198710A1 (en) * 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020254299A1 (en) * 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
AU2020326691A1 (en) * 2019-08-06 2022-03-03 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
EP4054585A1 (en) 2019-11-05 2022-09-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
CN115916170A (zh) 2020-04-17 2023-04-04 埃萨制药股份有限公司 固体形式的n-末端结构域雄激素受体抑制剂及其用途
WO2022046594A1 (en) * 2020-08-23 2022-03-03 Texas Biomedical Research Institute Treatment of infectious diseases using bcl-2 family protein inhibitors
CN112321526B (zh) * 2020-09-30 2023-09-22 西北师范大学 一种通过氧化还原-脱羧偶联反应合成杂芳甲胺类化合物的方法
CN116981451A (zh) * 2021-01-15 2023-10-31 田纳西大学研究基金会 用于治疗乳腺癌的药物组合物及其使用方法
US20220257552A1 (en) * 2021-02-11 2022-08-18 Veru, Inc. Methods of prescreening and treating breast cancers with selective androgen receptor modulators
MX2023011331A (es) * 2021-03-26 2023-10-03 Impact Therapeutics Shanghai Inc Capsula oral de inhibidor de parp y metodo de preparacion de la misma.
WO2023064782A2 (en) * 2021-10-12 2023-04-20 Baylor College Of Medicine Transcriptional reprogramming differentiates active from inactive esr1 fusions in endocrine therapy-refractory metastatic breast cancer

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1547758A (en) 1975-07-29 1979-06-27 Shell Int Research Herbicidal composition
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
UA51652C2 (uk) 1995-06-08 2002-12-16 Новартіс Аг Спосіб гідрування імінів
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
JP2000513362A (ja) 1996-06-27 2000-10-10 リガンド・ファーマスーティカルス・インコーポレーテッド アンドロゲン受容体モジュレーター化合物及び方法
US20090264534A1 (en) 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
FR2770842B1 (fr) 1997-11-13 1999-12-17 Oreal Nouveaux composes derives de n-aryl 2-hydroxy alkylamides
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6159959A (en) 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
WO2001036039A2 (en) 1999-11-17 2001-05-25 Novartis Ag Iontophoretic transdermal delivery of peptides
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
CN1281598C (zh) 1999-12-30 2006-10-25 信号药品公司 调节雌激素受体的化合物和方法
CA2413417A1 (en) 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
ES2283425T3 (es) 2000-08-03 2007-11-01 Antares Pharma Ipl Ag Nueva composicion para la administracion transdermica y/o transmucosa de compuestos activos que asegura niveles terapeutiocos adecuados.
AU2006201538B2 (en) 2000-08-24 2008-02-21 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
DE60124322T2 (de) 2000-08-24 2007-05-31 University Of Tennessee Research Foundation, Knoxville Selektive modulatoren des androgenrezeptors und methoden zu deren verwendung
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
ATE428466T1 (de) 2000-10-26 2009-05-15 Alza Corp Transdermales arzneistoffverabreichungssytem mit beschichteten mikrovorsprüngen
WO2003011824A1 (en) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7157604B2 (en) 2001-08-13 2007-01-02 Merck & Co., Inc. Selective estrogen receptor modulators
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
EP1474127B1 (en) 2002-02-15 2006-11-15 Endorecherche, Inc. Biphenyl derivatives and their use as antiandrogenic agents
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
CA2484038C (en) 2002-04-24 2011-10-18 Merck & Co., Inc. Estrogen receptor modulators
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
AU2003239869A1 (en) 2002-05-23 2003-12-12 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
US7799757B2 (en) 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
CA2492138C (en) 2002-07-12 2011-01-11 Yamanouchi Pharmaceutical Co., Ltd. N-phenyl-(2r,5s)dimethylpiperazine derivative
BR0313405A (pt) 2002-08-12 2005-07-12 Takeda Pharmaceutical Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
AU2003286757B2 (en) 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
UA79504C2 (en) 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
WO2004080377A2 (en) 2003-03-11 2004-09-23 Neurosearch A/S Kcnq channel modulating compounds and their pharmaceutical use
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
JP2007500245A (ja) 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物
EP1636167A2 (en) 2003-06-10 2006-03-22 SmithKline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
MXPA06000281A (es) 2003-06-30 2006-07-03 Johnson & Johnson Formulaciones para microproyecciones revestidas que contienen contraiones no volatiles.
CN1816324A (zh) 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
JP2007505120A (ja) 2003-09-10 2007-03-08 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節因子としての１７−複素環式−４−アザステロイド誘導体。
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
EP1680154B1 (en) 2003-10-31 2012-01-04 ALZA Corporation Self-actuating applicator for microprojection array
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
JP5388415B2 (ja) 2003-11-13 2014-01-15 アルザ・コーポレーシヨン 経皮送達のための組成物及び装置
WO2005049574A1 (en) 2003-11-20 2005-06-02 Warner-Lambert Company Llc Androgen receptor modulators
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
AU2005203922A1 (en) 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
UA85862C2 (uk) 2004-01-22 2009-03-10 Елі Ліллі Енд Компані Селективні модулятори рецепторів естрогену для лікування вазомоторних симптомів
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
EP1725522B1 (en) 2004-03-03 2014-09-10 GlaxoSmithKline LLC Aniline derivatives as selective androgen receptor modulators
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
JP2007223901A (ja) 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
EP1734964A4 (en) 2004-04-08 2009-06-17 Merck & Co Inc 17-BETA-ACETAMIDE-4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
WO2005111028A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
EP1771413B1 (en) 2004-05-03 2011-09-21 Janssen Pharmaceutica NV Benzofuran derivatives as selective androgen receptor modulators (sarms)
CA2565544A1 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Benzonitrile derivatives to treat musculoskeletal frailty
CA2566032A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
CA2566942A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
MXPA06013924A (es) 2004-05-29 2007-07-18 7Tm Pharma As Acidos tiazolaceticos sustituidos como ligandos crth2.
CA2543827C (en) 2004-06-07 2010-03-09 James T. Dalton Selective androgen receptor modulators and methods of use thereof
ES2422204T3 (es) 2004-09-10 2013-09-09 Janssen Pharmaceutica Nv Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
ES2366193T3 (es) 2004-09-20 2011-10-18 Janssen Pharmaceutica Nv Nuevos derivados que contienen heteroátomos tetracíclicos útiles como moduladores de receptores de hormonas esteroideas sexuales.
EP1805147B1 (en) 2004-09-30 2014-08-13 Janssen Pharmaceutica NV Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7834063B2 (en) 2004-10-13 2010-11-16 Glaxosmithkline Llc Benzonitryl and nitrobenzyl derivatives that modulate androgen receptors
AU2005310238A1 (en) 2004-10-29 2006-06-08 Merck Sharp & Dohme Corp. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
AU2005307003B2 (en) 2004-11-16 2011-10-13 Janssen Pharmaceutica N.V. Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs)
CA2587780A1 (en) 2004-11-18 2006-05-26 Transpharma Medical Ltd. Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents
EP1828195A2 (en) 2004-11-23 2007-09-05 PTC Therapeutics, Inc. Substituted phenols as active agents inhibiting vegf production
NZ555974A (en) 2005-01-10 2010-11-26 Acadia Pharm Inc Aminophenyl derivatives as selective androgen receptor modulators
US20080194536A1 (en) 2005-04-15 2008-08-14 Marlys Hammond Cyanoarylamines
CA2608419A1 (en) 2005-05-13 2006-11-23 Eli Lilly And Company Substituted n-arylpyrrolidines as selective androgen receptor modulators
WO2006133216A2 (en) 2005-06-06 2006-12-14 Smithkline Beecham Corporation 4-substituted arylamine derivatives and their use in pharmaceutical compositions
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
PL1902026T3 (pl) 2005-06-24 2010-07-30 Lilly Co Eli Pochodne tetrahydrokarbazolu użyteczne jako modulatory receptora androgenowego (SARM)
AR057656A1 (es) 2005-07-01 2007-12-12 Ligand Pharm Inc Compuestos moduladores de receptores de androgeno y metodods relacionados
US8592452B2 (en) 2005-08-01 2013-11-26 Takeda Pharmaceutical Company Limited Cyclic amine compound
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
US7776859B2 (en) 2005-10-14 2010-08-17 Bristol-Myers Squibb Company Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function
JP5449775B2 (ja) * 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
WO2007061781A1 (en) 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
TW200730505A (en) 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
EP1981547B1 (en) 2005-12-28 2015-09-30 Alza Corporation Stable therapeutic formulations
WO2007087518A2 (en) 2006-01-24 2007-08-02 Janssen Pharmaceutica N.V. 2-substituted benzimidazoles as selective androgen receptor modulators (sarms)
AU2007220419B2 (en) 2006-03-03 2012-03-15 Orion Corporation Selective androgen receptor modulators
CA2680690A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
AU2007275737A1 (en) 2006-07-19 2008-01-24 Osurf Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
CA2660570C (en) 2006-08-24 2016-08-09 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
ES2452343T3 (es) 2006-09-29 2014-04-01 Glaxosmithkline Llc Compuestos de indol sustituidos
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0722428A2 (pt) 2006-10-03 2013-11-26 Radius Health Inc Uso de composição estável no armazenamento
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2008128100A1 (en) 2007-04-13 2008-10-23 The Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
EP2146689B1 (en) 2007-04-16 2020-08-12 Corium, Inc. Solvent-cast microneedle arrays containing active
GB0712099D0 (en) 2007-06-22 2007-08-01 Wivenhoe Technology Ltd Transmission Of Audio Information
ES2406685T3 (es) 2007-08-07 2013-06-07 Takeda Pharmaceutical Company Limited Derivados de pirrolidin-2-ona como moduladores de los receptores de andrógenos
WO2009054988A1 (en) 2007-10-23 2009-04-30 Alza Corporation Transdermal sustained release drug delivery
US20110105554A1 (en) 2007-11-21 2011-05-05 Kinaris Biomedicals Gmbh Means for treating myosin-related diseases
BRPI0821676A2 (pt) 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
US8354446B2 (en) 2007-12-21 2013-01-15 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (SARMs) and uses thereof
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009105214A2 (en) 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
WO2009137104A1 (en) 2008-05-09 2009-11-12 Radius Health, Inc. Combination therapy for breastcancer comprising an antiestrogenic agent
DK2297100T3 (da) 2008-05-16 2012-12-17 Lilly Co Eli Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
WO2010074239A1 (ja) 2008-12-26 2010-07-01 久光製薬株式会社 マイクロニードルデバイス
JP5583694B2 (ja) 2009-01-05 2014-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するピロリジン化合物
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
ES2525353T3 (es) 2009-04-28 2014-12-22 Chugai Seiyaku Kabushiki Kaisha Derivado de espiroimidazolona
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
JP5606778B2 (ja) 2010-04-22 2014-10-15 大倉工業株式会社 手術用資材
US9687641B2 (en) 2010-05-04 2017-06-27 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
US9693950B2 (en) 2010-05-28 2017-07-04 3M Innovative Properties Company Aqueous formulations for coating microneedle arrays
US8642632B2 (en) * 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
CN103917242A (zh) 2011-04-22 2014-07-09 半径健康公司 PTH、PTHrP和相关肽的药物递送方法
CN104080441B (zh) 2011-11-30 2020-02-28 3M创新有限公司 包括肽治疗剂和氨基酸的微针装置、制备和使用其的方法
US9969683B2 (en) * 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) * 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) * 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) * 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
CN104812414A (zh) * 2012-11-28 2015-07-29 诺华股份有限公司 联合治疗
MA38656A1 (fr) 2013-06-11 2018-05-31 Bayer Pharma AG Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
JP2016524150A (ja) * 2013-06-19 2016-08-12 ユニヴァーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｉａｍｉ 乳癌の分類、予測及び処置のための分類システム、方法及びキット
AU2017281038B2 (en) 2016-06-22 2021-09-09 Ellipses Pharma Ltd AR+ breast cancer treatment methods

Also Published As

Publication number Publication date
WO2017223115A1 (en) 2017-12-28
IL292659A (en) 2022-07-01
AU2017281038A1 (en) 2019-01-03
CA3027563A1 (en) 2017-12-28
RU2018144427A (ru) 2020-07-22
AU2021282467B2 (en) 2024-02-08
US20200171008A1 (en) 2020-06-04
US20170368036A1 (en) 2017-12-28
MX2018015724A (es) 2019-04-29
EP3474841B1 (en) 2022-03-16
US20240207234A1 (en) 2024-06-27
JP7628560B2 (ja) 2025-02-10
KR20190021355A (ko) 2019-03-05
SI3474841T1 (sl) 2023-02-28
SMT202200199T1 (it) 2022-07-21
NZ749192A (en) 2022-07-29
US11771682B2 (en) 2023-10-03
RU2022108295A (ru) 2022-04-06
KR20240090491A (ko) 2024-06-21
EP3474841A1 (en) 2019-05-01
MX2022001075A (es) 2022-02-14
BR112018076001A2 (pt) 2019-03-26
JP2019518765A (ja) 2019-07-04
ES2913470T3 (es) 2022-06-02
EP4066827A1 (en) 2022-10-05
SG11201811225RA (en) 2019-01-30
KR102397890B1 (ko) 2022-05-12
IL263678B (en) 2022-06-01
RS63311B1 (sr) 2022-07-29
PL3474841T3 (pl) 2022-07-11
IL263678A (en) 2019-01-31
EP3474841A4 (en) 2020-07-22
LT3474841T (lt) 2022-06-10
RU2769527C2 (ru) 2022-04-01
RU2018144427A3 (da) 2020-10-16
JP2023055861A (ja) 2023-04-18
KR20220035276A (ko) 2022-03-21
AU2017281038B2 (en) 2021-09-09
PT3474841T (pt) 2022-06-20
AU2021282467A1 (en) 2022-01-06
JP7221699B2 (ja) 2023-02-14
HRP20220619T1 (hr) 2023-02-03

Similar Documents

Publication Publication Date Title
DK3474841T3 (da) Fremgangsmåder til behandling af ar+-brystkræft
DK3431105T3 (da) Medicinsk sammensætning til behandling af cancer
HK1247202A1 (zh) 用於治療癌症的化合物
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
HUE059694T2 (hu) Készítmény rák kezelésére
PL3283527T3 (pl) Leczenie skojarzone nowotworów
RS64787B1 (sr) Lečenje lag-3-pozitivnih tumora
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
EP3601536A4 (en) TREATMENT PROCESSES
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
IL259996A (en) Combinations for cancer treatment
DK3458052T3 (da) Kombinationsbehandling af cancer
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
EP3474854A4 (en) DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER
DK3518932T3 (da) Behandling af prostatacancer
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
DK3400072T3 (da) Formuleringer til behandling af blærecancer
DK3576740T3 (da) Cancerbehandling
DK3638293T3 (da) Sammensætninger til behandling af cancer
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
DK3525774T3 (da) Lasofoxifen behandling af er+ brystcancer
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
IL263835A (en) Exosome-guided treatment of cancer